Hainan Shuangcheng Pharmaceuticals Co., Ltd.
Symbol: 002693.SZ
SHZ
5.16
CNYTrhová cena dnes
2237.9007
Pomer P/E
-128.6793
Pomer PEG
2.14B
MRK Cap
- 0.00%
Výnos DIV
Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693-SZ) Finančné výkazy
Súvaha
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 512.21 | 146 | 77 | 100 | ||||||||||||||
balance-sheet.row.short-term-investments | 447.02 | 133.8 | 55.4 | 94.3 | ||||||||||||||
balance-sheet.row.net-receivables | 144.81 | 41 | 33.1 | 44.6 | ||||||||||||||
balance-sheet.row.inventory | 291.75 | 65.4 | 55.2 | 52.8 | ||||||||||||||
balance-sheet.row.other-current-assets | 0.05 | 0 | 0.1 | 0 | ||||||||||||||
balance-sheet.row.total-current-assets | 948.81 | 252.4 | 165.4 | 197.5 | ||||||||||||||
balance-sheet.row.property-plant-equipment-net | 1849.45 | 471.8 | 504.7 | 541 | ||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||||
balance-sheet.row.intangible-assets | 668.54 | 164.9 | 156.9 | 134.4 | ||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 668.54 | 164.9 | 156.9 | 134.4 | ||||||||||||||
balance-sheet.row.long-term-investments | 42.28 | 8.8 | 17.3 | 25.9 | ||||||||||||||
balance-sheet.row.tax-assets | 3.67 | 1 | 1 | 0.7 | ||||||||||||||
balance-sheet.row.other-non-current-assets | 53.66 | 12.2 | 9.1 | 8.3 | ||||||||||||||
balance-sheet.row.total-non-current-assets | 2617.6 | 658.6 | 689.1 | 710.2 | ||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||
balance-sheet.row.total-assets | 3566.42 | 911 | 854.6 | 907.7 | ||||||||||||||
balance-sheet.row.account-payables | 59.55 | 15.5 | 17.2 | 15.4 | ||||||||||||||
balance-sheet.row.short-term-debt | 774.46 | 205.3 | 0.3 | 55.7 | ||||||||||||||
balance-sheet.row.tax-payables | 23.85 | 12.8 | 7.2 | 6.3 | ||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 167 | 167 | ||||||||||||||
Deferred Revenue Non Current | 30.41 | 7.6 | 8.9 | 10.3 | ||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 12.16 | - | - | - | ||||||||||||||
balance-sheet.row.other-current-liab | 144.47 | 73.6 | 1.8 | 1.5 | ||||||||||||||
balance-sheet.row.total-non-current-liabilities | 42.56 | 10.7 | 179.4 | 180 | ||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | ||||||||||||||
balance-sheet.row.total-liab | 1235.79 | 330.1 | 287.8 | 309.4 | ||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||
balance-sheet.row.common-stock | 1662.29 | 414.7 | 412 | 405 | ||||||||||||||
balance-sheet.row.retained-earnings | -1173.2 | -296.2 | -305.2 | -284.6 | ||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 1000.92 | 87.2 | 82.2 | 86 | ||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 600.88 | 307.9 | 292.9 | 286.5 | ||||||||||||||
balance-sheet.row.total-stockholders-equity | 2090.9 | 513.5 | 481.8 | 492.9 | ||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 3566.42 | 911 | 854.6 | 907.7 | ||||||||||||||
balance-sheet.row.minority-interest | 239.74 | 67.4 | 84.9 | 105.4 | ||||||||||||||
balance-sheet.row.total-equity | 2330.63 | 580.9 | 566.8 | 598.3 | ||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 3566.42 | - | - | - | ||||||||||||||
Total Investments | 447.02 | 133.8 | 55.4 | 94.3 | ||||||||||||||
balance-sheet.row.total-debt | 774.46 | 205.3 | 167.3 | 222.7 | ||||||||||||||
balance-sheet.row.net-debt | 709.27 | 193.1 | 145.6 | 216.9 |
Výkaz peňažných tokov
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0.93 | -8.5 | -40.8 | -79.9 | ||||||||||||||
cash-flows.row.depreciation-and-amortization | 16.06 | 57.5 | 54.3 | 57.1 | ||||||||||||||
cash-flows.row.deferred-income-tax | 5.29 | -0.4 | 0.4 | 1.2 | ||||||||||||||
cash-flows.row.stock-based-compensation | 8.3 | 6.9 | 7.2 | -1.2 | ||||||||||||||
cash-flows.row.change-in-working-capital | -23.72 | -4.5 | 14.9 | -12.2 | ||||||||||||||
cash-flows.row.account-receivables | -13.83 | -13.8 | 5.4 | 39.8 | ||||||||||||||
cash-flows.row.inventory | -9.89 | -9.9 | -4.8 | -4.3 | ||||||||||||||
cash-flows.row.account-payables | 0 | 19.6 | 13.8 | -48.9 | ||||||||||||||
cash-flows.row.other-working-capital | 0 | -0.4 | 0.4 | 1.2 | ||||||||||||||
cash-flows.row.other-non-cash-items | -5.52 | -25.8 | -12.5 | 24.5 | ||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -0.08 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -39.11 | -33 | -31.6 | -51.6 | ||||||||||||||
cash-flows.row.acquisitions-net | 30.81 | 27 | 21.7 | 53.6 | ||||||||||||||
cash-flows.row.purchases-of-investments | -418.83 | -471 | -256.2 | -637.2 | ||||||||||||||
cash-flows.row.sales-maturities-of-investments | 456.59 | 391.9 | 299.2 | 615.3 | ||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | -51.6 | ||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 29.47 | -85.1 | 33 | -71.5 | ||||||||||||||
cash-flows.row.debt-repayment | -60.74 | -12 | -55.3 | -1.8 | ||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.dividends-paid | -8.7 | -11.1 | -9.1 | -9.8 | ||||||||||||||
cash-flows.row.other-financing-activites | 38.34 | 68.1 | 23.8 | 57 | ||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -31.1 | 44.9 | -40.6 | 45.4 | ||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | -0.02 | 0.1 | -0.1 | -0.3 | ||||||||||||||
cash-flows.row.net-change-in-cash | 1.46 | -14.8 | 15.8 | -36.9 | ||||||||||||||
cash-flows.row.cash-at-end-of-period | 59.79 | 6.8 | 21.6 | 5.8 | ||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 58.33 | 21.6 | 5.8 | 42.7 | ||||||||||||||
cash-flows.row.operating-cash-flow | -0.08 | 25.2 | 23.6 | -10.5 | ||||||||||||||
cash-flows.row.capital-expenditure | -39.11 | -33 | -31.6 | -51.6 | ||||||||||||||
cash-flows.row.free-cash-flow | -39.19 | -7.8 | -8.1 | -62.1 |
Riadok výkazu ziskov a strát
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 259.14 | 274.8 | 320.3 | 269.4 | ||||||||||||||
income-statement-row.row.cost-of-revenue | 77.43 | 88.3 | 81.4 | 60.2 | ||||||||||||||
income-statement-row.row.gross-profit | 181.71 | 186.5 | 238.9 | 209.3 | ||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||
income-statement-row.row.research-development | 14.15 | - | - | - | ||||||||||||||
income-statement-row.row.selling-general-administrative | 14.02 | - | - | - | ||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 115.8 | - | - | - | ||||||||||||||
income-statement-row.row.other-expenses | 71.77 | 63.2 | 69 | 69.7 | ||||||||||||||
income-statement-row.row.operating-expenses | 210.16 | 215.8 | 282.7 | 264.6 | ||||||||||||||
income-statement-row.row.cost-and-expenses | 287.59 | 304.1 | 364.1 | 324.8 | ||||||||||||||
income-statement-row.row.interest-income | 0.1 | 0.1 | 0.1 | 0.1 | ||||||||||||||
income-statement-row.row.interest-expense | 10.15 | 11.2 | 9 | 10 | ||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 115.8 | - | - | - | ||||||||||||||
income-statement-row.row.total-other-income-expensenet | -0.05 | 15.6 | 2 | -25.6 | ||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||
income-statement-row.row.other-operating-expenses | 71.77 | 63.2 | 69 | 69.7 | ||||||||||||||
income-statement-row.row.total-operating-expenses | -0.05 | 15.6 | 2 | -25.6 | ||||||||||||||
income-statement-row.row.interest-expense | 10.15 | 11.2 | 9 | 10 | ||||||||||||||
income-statement-row.row.depreciation-and-amortization | -9.92 | 57.5 | 54.3 | 57.1 | ||||||||||||||
income-statement-row.row.ebitda-caps | -22.8 | - | - | - | ||||||||||||||
income-statement-row.row.operating-income | -12.88 | -24.5 | -42.3 | -53.2 | ||||||||||||||
income-statement-row.row.income-before-tax | -12.93 | -8.9 | -40.4 | -78.8 | ||||||||||||||
income-statement-row.row.income-tax-expense | -8.64 | -0.4 | 0.4 | 1.2 | ||||||||||||||
income-statement-row.row.net-income | 0.93 | -8.5 | -40.8 | -79.9 |
Často kladené otázky
Čo je Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) celkové aktíva?
Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) celkové aktíva sú 911018789.000.
Aký je ročný obrat podniku?
Ročné príjmy sú 100763670.000.
Aké je ziskové rozpätie podniku?
Zisková marža firmy je 0.701.
Aký je voľný peňažný tok podniku?
Voľný peňažný tok je -0.095.
Aká je čistá zisková marža podniku?
Čistá zisková marža je 0.004.
Aké sú celkové výnosy podniku?
Celkové príjmy sú -0.050.
Aká je Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) čistý zisk (čistý príjem)?
Čistý zisk (čistý príjem) je -8496001.960.
Aký je celkový dlh firmy?
Celkový dlh je 205303152.000.
Aké je číslo prevádzkových nákladov?
Prevádzkové výdavky sú 215787255.000.
Aký je údaj o hotovosti spoločnosti?
Peňažné prostriedky podniku sú 3712099.000.